These results are based on all of the participants in the trials, i.e. more than 2,200 people, and confirm what was announced in early November from preliminary results.
No deaths were recorded among those who received the treatment. Participants were unvaccinated and at high risk of developing a severe case of COVID-19.
Pfizer also announced that its antiviral treatment, which will be marketed as Paxlovid, is expected to remain effective against the Omicron variant.
This highlights the potential of this [médicament] candidate to save the lives of patients around the worldPfizer CEO Albert Bourla said in a statement.
Variants of concern like Omicron have exacerbated the need for accessible treatment options for those who contract the virus, he added.
Antivirals work by reducing the ability of a virus to replicate, thereby slowing down the disease. These treatments represent a key complement to vaccines to protect against COVID-19, in particular because they are very easy to administer, being able to be taken simply at home with a large glass of water.
Pfizer is also the source of one of the most widely used COVID-19 vaccines in the world.